Pfizer, Moderna, J&J See Respiratory Virus RSV as Next Vaccine Target
April 15, 2022
(Wall Street Journal) – After Covid-19, vaccine makers’ next big target is a respiratory virus that kills up to 500 children a year nationwide and has been among the leading causes of U.S. hospitalizations for decades. The respiratory syncytial virus, or RSV, infects nearly everyone at some point, causing mild, cold-like symptoms for most people. But it can lead to serious health problems such as difficulty breathing and pneumonia for infants and older adults. The virus has for decades eluded efforts to develop a vaccine, including a major setback in the 1960s when an experimental shot harmed some children in testing. RSV is one of the last remaining childhood diseases without an approved vaccine. (Read More)